Crossmark

Halofuginone ameliorates the susceptibility to atrial fibrillation by activating the PI3K/Akt signaling pathway

Published Online: 2024-09-24

Published Print: 2024-12

Authors

Xu, Feng

Zhao, Xiaolong

Zhang, Jing

Shen, Chunjian
Funding

Funding for this research was provided by:

Health Commission of Shenyang
License Information

Text and Data Mining valid from 2024-09-24

Version of Record valid from 2024-09-24
More Information

Article History

Received: 7 September 2023

Accepted: 10 September 2024

First Online: 24 September 2024

Declarations

:

: The authors declare no competing interests.

Document is current